Clinical workout for the early detection of cognitive decline and dementia

Aging is the major risk factor for the development of human neurodegenerative maladies such as Alzheimer's, Huntington's and Parkinson's diseases (PDs) and prion disorders, all of which, stem from toxic protein aggregation All of these diseases are correlated with cognitive decline. Cognitive Decline is a dynamic state from normal cognition of aging to dementia. According to the original criteria for Alzheimer's Disease (AD) (1984), a Clinical diagnosis was possible only when someone was already demented. The prevalence rates Of Cognitive Decline (mild cognitive impairment plus dementia) are Very-high now and will be higher in future because of the increasing Survival time of people. Many neurological and psychiatric diseases are correlated with cognitive decline. Diagnosis of,cognitive decline is mostly clinical (clinical criteria), but there are Multiple biomarkers that could help us Mostly in research programs such as short or long, paper and pencil or computerized neuropsychological batteries for cognition, activities of daily living and behavior, electroencephalograph, event-related potentials, and imaging-structural Magnetic resonance imaging (MRI) and functional (fMRI, Pittsburgh bound positron emission tomography,FDG-PET, single photon emission computerized tomography and imaging of tau pathology)-cerebrospinal fluid proteins (Abeta; tau and phospho-tau in AD and alpha-Synuclein (alpha Syn) for PD). Blood biomarkers need more studies to confirm their usefulness. Genetic markers are also Studied but until now are not used in clinical praxis. Finally, in everyday clinical praxis and in research workout for early detection of cognitive decline, the combination of biomarkers is useful.